Printer Friendly

EXIQON REPORTS POSITIVE CLINICAL DATA FROM EORTC TRIAL.

The European Organization for Research and Treatment of Cancer (EORTC) has undertaken a multi-institutional prospective randomized clinical trial on 719 late stage epithelial ovarian cancer patients (named 55971). Results were announced at the 2008 International Gynecologic Cancer Society (IGCS) biennial meeting in Bangkok, Thailand. In this study, Oncotech EDR Assays were performed on biopsies obtained from 246 patients. Results clearly demonstrate that resistance to carboplatin, as identified by the Oncotech EDR Assay, was a significant independent predictor for response to first-line treatment in advanced ovarian cancer patients.

The clinical trial results demonstrate that the use of the Oncotech EDR Assay predictive test can predict resistance to platinum-based chemotherapy before therapy is initiated. These results are important to ovarian cancer treating physicians since ovarian cancer is known to show resistance to platinum-based agents. Currently, the standard first-line treatment regimen for late stage ovarian cancer contains platinum-based chemotherapy.

Dr. Ignace Vergote, President of the IGCS and Coordinator of the trial, commented, "The results of this study provide additional evidence that resistance to a platinum-based therapy, as predicted by the Oncotech EDR Assay, is a significant negative predictor of response to first line platinum-based chemotherapy. This information is important since it allows the treating physician to consider alternative regimens earlier in the treatment plan which might benefit the patient."

Dr. Cynthia French, Exiqon Diagnostics Chief Scientific Officer, stated, "The Oncotech EDR Assay has once again been proven through clinical studies to be a valuable tool in individualizing medicine for cancer patients. We are very pleased to share the positive results of this trial conducted by the prestigious EORTC and are looking forward to continue to collaborate with key research organizations to support the clinical use of the Oncotech EDR Assay."

Lars Kongsbak, CEO says: "This study is an important part of our effort to create an expanding portfolio of clinical studies supporting our diagnostic tests. Clinical evidence of this kind accomplishes three objectives: to demonstrate to the pharmaceutical research and clinical oncology communities that the Oncotech EDR Assay platform is a validated testing instrument leading to increased adoption by the oncology community; to strengthen clinical support of the Oncotech EDR Assay technology required by healthcare insurers for optimal reimbursement; and to validate the Oncotech EDR Assay results further substantiating the technology as a key platform that can be leveraged as a reference in the identification of molecular signatures of chemoresistance. The latter is offered to our customers through Exiqon Pharma Services."

For more information, call 415/817-2539.
COPYRIGHT 2008 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Article Type:Clinical report
Date:Dec 1, 2008
Words:414
Previous Article:QRXPHARMA/UNIV. OF ALABAMA COLLABORATE FOR PARKINSON'S RESEARCH.
Next Article:FDA APPROVES CEPHALON TREANDA TO TREAT NON-HODGKINS LYMPHOMA.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters